A SU2C Catalyst Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Paricalcitol (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 23 May 2018 Planned End Date changed from 15 Jun 2019 to 15 Dec 2019.
- 23 May 2018 Planned primary completion date changed from 15 Jan 2019 to 15 May 2019.